The Institute for Clinical and Economic Review (ICER) on Friday released a draft evidence report analyzing the comparative clinical effectiveness of Akcea Therapeutics’ inotersen and Alnylam Pharmaceuticals’ patisiran for hereditary transthyretin-related amyloidosis.
According to a press release, the report and draft voting questions are open to public comment until Aug. 17.
The Midwest Comparative Effectiveness Public Advisory Council is set to consider the report during a public meeting in September this year.
“During this review, ICER spoke with key patient groups and advocates, clinical experts, and manufacturers,” a press release states.
To read the full press release, click here.